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ORIGINAL REPORT
Prescriptive contraceptive use among isotretinoin users in the
Netherlands in comparison with non-users: a drug utilisation study
Hubertina J.M.J. Crijns1,2*, Nienke van Rein1, Christine C. Gispen-de Wied2, Sabine M. Straus2,3 and
Lolkje T.W. de Jong-van den Berg1
1University of Groningen, Department of Pharmacoepidemiology & Pharmacoeconomics, Groningen, the Netherlands
2Medicines Evaluation Board, The Hague, the Netherlands
3Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands
ABSTRACT
Purpose To assess the compliance with the isotretinoin Pregnancy Prevention Programme (PPP) by evaluating the use of prescribed contracep-
tives among isotretinoin users. The PPP contains a requirement for the use of contraceptive methods for women of childbearing potential.
Methods A drug utilisation study was performed using data from a drug prescription database (containing Dutch community pharmacy
data) covering a population of 500 000 patients. Contraceptive use in female isotretinoin users and in a reference group of female non-
isotretinoin users (aged 15–49 years) was compared using data from 1999 until 2006 in 2-year periods. Descriptive statistics were used.
Results Of the female isotretinoin users (n= 651), 52%–54% ﬁlled prescriptions on contraceptives in strict accordance to the PPP, used
before, during, and after discontinuation of isotretinoin, compared with 39%–46% in the reference group. A more liberal approach of a
minimum of one prescription for a contraceptive method showed 61%–64% use of contraceptives among isotretinoin users. Similar patterns
were seen when data were broken down in age groups. Furthermore, a higher proportion of female patients using isotretinoin prescribed by
general practitioners used prescribed contraceptives compared with those receiving isotretinoin by specialists.
Conclusion Compliance with the contraceptive use according to a PPP for a teratogenic drug such as isotretinoin is 52%–64%, which is
lower than anticipated. Reasons for the low compliance will need to be clariﬁed before further measures can be taken. Copyright © 2012
John Wiley & Sons, Ltd.
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INTRODUCTION
Isotretinoin is a vitamin A derivative used for the
treatment of severe acne that has failed to respond to
conventional acne therapy.
Dutch studies on the prevalence of acne in general
practice showed a range between 30% and 90%,
depending on the deﬁnition.1 A study in the UK2 and
a study in Germany3 show a prevalence of clinical
acne in women of 23% and 24%, respectively. Only
10% of both male and female acne patients experience
severe acne, deﬁned as having at least 20 papules and/
or pustules had used systemic treatment, and <1% of
all acne patients ever used isotretinoin.4
Because vitamin A derivatives are highly teratogenic
in humans, a strict Pregnancy Prevention Programme
(PPP) is in place.
Isotretinoin was authorised in the USA in 1982 and
in Europe in 1983. In 1983,5 the ﬁrst cases of congen-
ital anomalies appeared despite a contraindication for
pregnancy because of the teratogenic risk of vitamin A
derivatives. Therefore, in 1983, the product information
was revised by the Marketing Authorisation Holder
(MAH), Roche. Additional steps were taken such as
placing a text about teratogenicity in the product infor-
mation, and letters were sent to prescribers and pharma-
cists with additional information on the warnings.
Worldwide, a PPP was implemented by Roche in
1988. In the USA, this PPP has been amended twice
thereafter, in 2001 (System toManage Accutane Related
Teratogenicity [SMART]) and in 2006 (iPLEDGE; a
more stringent programme in which prescribers, patients,
*Correspondence to: H. Crijns, Medicines Evaluation Board, Kalvermarkt 53,
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No ethical approval was necessary for this study.
Copyright © 2012 John Wiley & Sons, Ltd.
pharmacoepidemiology and drug safety 2012; 21: 1060–1066
Published online 6 January 2012 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3200
pharmacists, and wholesalers are registered in an online
database).6 In 2003, in Europe, due to the entrance of
generic products containing isotretinoin on the market,
a regulatory referral was performed to harmonise the
indication for isotretinoin as well as the PPP.7 The
prevalence of congenital anomalies with isotretinoin is
about 26% in live births.8 The aim of these PPPs is to
avoid pregnancies before, during the use, and 1 month
after discontinuation of isotretinoin because of the high
risk of congenital anomalies.
A PPP is a risk minimisation measure as deﬁned in
the guideline9 on risk management plans. In this case,
the risk on exposure to isotretinoin during pregnancy
and indirectly a risk on congenital anomalies should
be avoided. Elements of the PPP of isotretinoin are
presented in Box 1. The use of contraceptives by
female isotretinoin users might provide an indication
of the effect of the PPP.
During recent years, cases of in utero exposure of
isotretinoin have been identiﬁed despite the PPP.10,11
For regulatory authorities, it is important to gain
insight in the compliance with the PPP, which is
intended to gain 100% avoidance of pregnancies.
The use of contraception by female isotretinoin users
could be an indication of compliance with the PPP,
which can be assessed and quantiﬁed in contrast to
some of the other elements of the PPP. We performed
a drug utilisation study with the data of a Dutch com-
munity pharmacies database (IADB.nl) to evaluate the
use of contraceptives among female isotretinoin users
as main outcome. To measure whether the PPP had
effect, the use of contraceptives in female isotretinoin
users was compared with contraceptive use in the gen-
eral population in the same age group. In addition, we
evaluated different aspects (e.g. compliance in urban
vs. rural areas, innovator product vs. generic formula-
tions of isotretinoin, ﬁrst prescriber and isotretinoin
preceded by prescribed conventional therapy vs. no
preceding conventional therapy ) that might inﬂuence
the use of contraceptives and thereby indirectly the
adherence to the PPP.
MATERIALS AND METHODS
Database
Data of Dutch community pharmacies are obtained
from IADB.nl12: a database which contains prescrip-
tions of a population of approximately 500 000 indi-
viduals from the Netherlands. The data in the database
consist of among others personal characteristics (an
anonymous identiﬁer, gender, and date of birth) and
drug information as Anatomical Therapeutic Chemical
(ATC) code13 of the World Health Organisation, the
dispensing date, the theoretical end date, and the
prescriber.12,14 Dutch patients commonly register with
one pharmacy and mainly obtain their prescription
medication from this pharmacy, so medication histo-
ries of patients can be considered nearly complete.15
Study population
The study covered the period of 1999 to 2006. Both
males and females aged 15–49 years using isotretinoin
were selected (n = 1825).
Isotretinoin users to be included in the study were
determined by the ﬁrst prescription of isotretinoin in
the database, which has to be at least 180 days after
the date the patient ﬁrst appeared in the database.
The prevalence rates of male and female isotretinoin
users were compared in general and speciﬁcally for
ﬁrst-time prescribers of isotretinoin, for example,
specialists or general practitioners (GPs).
Reference population
The population aged 15–49 years in the area covered
by the community pharmacies participating in the data
base during the period 1999–2006.
Isotretinoin use among female users
We selected in this dataset female patients aged
15–49 years who had received any isotretinoin pre-
scription during the study period. Two-year preva-
lence of female isotretinoin users was calculated. The
ATC code for systemic isotretinoin, D10BA01, was
used. The 2-year prevalence was deﬁned as the num-
ber of female isotretinoin users who received at least
one prescription in a 2-year period divided by the
population in that age group.
Contraceptive use among female isotretinoin users
We selected in this dataset female patients aged
15–49 years who had received any isotretinoin pre-
scription during the study period. In this group of
isotretinoin users (n = 651), contraceptive use was cal-
culated and compared with the use of contraceptives in
the population of female non-users of isotretinoin
between 15 and 49 years of age (reference group).
Prescriptive contraceptive methods have been
deﬁned as all forms of intrauterine devices (IUDs),
hormonal implants, oral contraceptives (including
cyproteron acetate/ethinyl-estradiol [CPA/EE]) and
depot medroxyprogesterone acetate. The period of use
for these contraceptions was considered to be 1 year
for the oral and depot contraceptives, 3 years for the
hormonal implants, and 5 years for the IUDs.
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The use of contraceptive methods among isotreti-
noin users was calculated by two methods: (i) a liberal
method: the number of women who had at least one
prescription of a contraceptive in the period described
earlier for the different contraceptive methods as the
isotretinoin prescription divided by the total number
of isotretinoin users and (ii) a strict method, in which
the period of contraceptive use has been deﬁned as
30 days before isotretinoin was used, the duration of
its use, and 30 days after the use of isotretinoin ended.
The use of contraceptives in the reference group was
calculated as the number of women (isotretinoin non-
users) in the age group of 15 through 49 years with
at least one contraceptive prescription divided by the
female population (15–49 years) of the covered area.
Other variables
Among the female isotretinoin users, we also com-
pared compliance to the PPP related with other vari-
ables such as area (rural vs. urban), type of isotretinoin
formulation (innovator product vs. generic products),
ﬁrst prescriber of isotretinoin (specialist vs. GP),
preceding use of conventional anti-acne medication,
and type of contraceptive (CPA/EE vs. others).
• Urban areas are deﬁned as cities with at least 100 000
citizens, and rural areas were all other areas. There
have been suggestions of better adherence differences
on drug use in rural areas compared with urban
areas,16,17 which triggered the question on the compli-
ance of contraceptives and isotretinoin in these areas.
• The performance with the innovator product
RoaccutaneW was compared with the performance
using generic products of isotretinoin. The innovator
and the generic products were determined by the
trading product code (hpk in Dutch) number, an
identiﬁcation number for every product that is on
the market in the Netherlands that can distinguish
different brands.18 The MAH of the innovator
RoaccutaneW with long-time experience with a
PPP for isotretinoin in contrast with the MAH of
generic products of isotretinoin but despite the
harmonised European PPP for isotretinoin was con-
sidered useful in comparing compliance with the
contraceptive use as part of the PPP among these
products.
• Contraceptives prescribed for female isotretinoin
users with ﬁrst prescriber of isotretinoin, specialist,
or GP were analysed. Isotretinoin may be prescribed
by physicians known with the product. A study per-
formed in France19 showed that GPs did perform
less than dermatologists.
• Conventional anti-acne medication was deﬁned as
the ﬁrst-line medication for treatment of acne
according to standards for dermatologists and for
Dutch GPs.20 Contraceptive use in female isotreti-
noin users with prescribed conventional anti-acne
medication before isotretinoin use was compared
with those without preceding prescriptions of con-
ventional anti-acne medication. Prescription of
conventional medication before isotretinoin is part
of a guideline,1 considering PPP as a guideline;
therefore, the theory that in case a prescriber did
not follow one guideline he or she would also not
follow the PPP for isotretinoin.
• Proportion of users of the combination preparation
of CPA/EE in the female isotretinoin user group
was compared with the proportion of CPA/EE in
the reference group. CPA/EE is not licensed as a
contraceptive;21 it is licensed for the treatment of
acne in female patients, but it also has contraceptive
properties and therefore used as such in daily prac-
tice. From literature,22 it is known that the women
with acne will more often use CPA/EE as a con-
traceptive, despite that it is not licensed for this
indication.
Statistics
Descriptive statistics were used, and calculation of
proportions was in percentage with 95% conﬁdence
intervals (95%CI), if applicable. Based on these con-
ﬁdence intervals, statistical signiﬁcant differences with
the reference population could be determined.
RESULTS
During 1999–2006, we identiﬁed 1825 isotretinoin
users in the IADB.nl database between 15 and 49 years
of age. The group of isotretinoin users consisted of
64% male users (n= 1171) and 36% female users
(n= 651).
The proportion of female isotretinoin users versus
male patients was higher with the specialist compared
with the GP, 64% and 40%, respectively.
The prevalence of contraceptive use among the
female isotretinoin users in both analyses the more
strict (52%–54%) and the more liberal (61%-64%)
deﬁnition and was compared with contraceptive use
in the female general population (39%–46%), showing
a signiﬁcant higher proportion of contraceptive use in
both isotretinoin groups (see Table 1 and Figure 1).
Rural areas have a better compliance with contra-
ceptive use compared with the urban area (see Table 1).
In the periods 2003–2004 and 2005–2006, there is
h. j. m. j. crijns et al.1062
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even an increase in compliance in the rural areas com-
pared with the urban areas. Compared with a reference
group of contraception users, the urban female isotreti-
noin users have a lower proportion of contraception
use from 2003 onward (see Table 1). Rural female
isotretinoin users with contraception have a better
compliance than that of a reference group of rural
contraception users from 2003 onward (see Table 1).
Use of contraceptives with the innovator product
versus the generic products containing isotretinoin
was compared. The generic isotretinoin formulations
came on the market from 2003 onward; only the last
Table 1. Data from the female population aged 15–49 years in the database for different variables
1999–2000 2001–2002 2003–2004 2005–2006
Isotretinoin and contraceptives (PPP)*,
n (%, [95%CI])
121 (54, [47–61])† 108 (54, [47–61])† 103 (54, [47–61])† 83 (52, [44–60])†
Isotretinoin and contraceptives{,
n (%, [95%CI])
142 (64, [57–70])† 124 (62, [56–69])† 116 (61, [54–67])† 98 (62, [54–69])†
Reference group and contraceptives,
n (%, [95%CI])
80 778 (45.7 [45.5–45.9] 80 412 (44.6 [44.4–44.8] 80 814 (43.0 [42.8–43.2] 79 944 (39.1 [38.9–39.3]
Age (years), n (%)
15–24
Isotretinoin and contraceptives (PPP) 47 (62) 48 (57) 44 (55) 36 (50)
Reference group and contraceptives 28 846 (54) 28 646 (56) 28 968 (56) 28 139 (51)
25–34
Isotretinoin and contraceptives (PPP) 51 (61) 44 (61) 38 (53) 29 (63)
Reference group and contraceptives 30 894 (54) 29 353 (56) 28 607 (55) 27 496 (51)
35–49
Isotretinoin and contraceptives (PPP) 23 (37) 16 (37) 21 (55)† 18 (44)†
Reference group and contraceptives 20 392 (25) 21 681 (26) 22 372 (25) 23 320 (23)
Innovator versus generic isotretinoin,
n (%)
Innovator with contraceptives 121 (54) 108 (54) 63 (56) 48 (66)}
Generic with contraceptives – – 57 (55) 44 (45)
Urban areas versus rural areas, n (%)
Urban
Isotretinoin users and contraceptives 78 (53) 66 (54) 58 (49) 41 (43)
Reference group and contraceptives 46 660 (56) 44 715 (55) 43 544 (54) 41 401 (52)
Rural
Isotretinoin users and contraceptives 43 (56) 42 (55) 45 (63) 42 (67)}
Reference group and contraceptives 33 291 (57) 33 480 (57) 33 279 (56) 32 306 (53)
CI, conﬁdence interval; PPP, Pregnancy Prevention Programme.
*Strict contraceptive use in accordance with PPP.
†Statistically signiﬁcantly higher compared with the reference group.
{Liberal contraceptive use.
}Statistically signiﬁcantly higher compared with the comparator group generic formulations.
}Statistically signiﬁcantly higher compared with the urban isotretinoin users group and to the rural reference group.
Figure 1. Distribution (%) of prescribed contraceptives in isotretinoin users according to the strict deﬁnition of the PPP and controls. PPP, Pregnancy Pre-
vention Programme
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2-year periods have data for comparison and show a
statistically better performance in the innovator prod-
uct in the period 2005–2006 (see Table 1).
The compliance of contraceptive use with the origin
of ﬁrst prescriptions of isotretinoin was compared. The
proportion of contraceptive users in the female popu-
lation was signiﬁcantly lower in the specialist group
compared with the GP group, 63% versus 71%,
respectively.
The use of prescribed contraceptives in female iso-
tretinoin users who had prescriptive conventional
treatment of acne preceding use of isotretinoin was
compared with isotretinoin use without preceding pre-
scribed conventional acne therapy. The proportion of
prescribed contraceptives in the group of female iso-
tretinoin users with preceding conventional anti-acne
treatment was 66% (61–71 [95%CI], n = 236) com-
pared to 41% (32–50 [95%CI], n= 46) in the group
without preceding conventional anti-acne medication,
which is statistically signiﬁcantly higher. The compli-
ance of specialists and GPs in the group of female
isotretinoin users with preceding prescriptive conven-
tional anti-acne medication and contraception was
similar, 52% and 48%, respectively. However, in the
group of female isotretinoin users without preceding
prescriptive conventional anti-acne medication and
contraception, the compliance of specialists was
higher than GPs, 63% and 37%, respectively.
The proportion of CPA/EE of the contraceptives
used in the isotretinoin user group is 59.9%. In the
reference group, the use of CPA/EE is below 9.6%
of the contraceptive use.
DISCUSSION
In this study, a signiﬁcantly higher use of prescribed
contraceptives was found among female isotretinoin
users using contraceptives in accordance with the
PPP (52%–54%) as well as with the liberal use of a
minimum of one prescription of a contraceptive
method (61%–64%) compared with the use of pre-
scribed contraceptives in the female general popula-
tion, reference group (39%–46%). Compliance to
contraceptive use among female isotretinoin users
was also better in rural versus urban areas as well as
with preceding therapy of conventional anti-acne treat-
ment compared with no preceding therapy. Further-
more, female patients using isotretinoin prescribed
by general practitioners had a better performance com-
pared with those receiving isotretinoin by specialists.
Limitation of the study is the lack of information on
barrier methods, such as condom use, and on sterilisa-
tion of the female isotretinoin users. Therefore, there
will be underrating of the contraceptive methods for
both isotretinoin users and the reference group. For
example, for 2008, Statistics Netherland23 shows that
a proportion of 3% of all Dutch women are sterilised
and that 9% used a condom for contraception. Further
limitation might be the lack of explanations for the
lower compliance with contraceptive use among
female urban isotretinoin users and contraception even
lower than the reference group.
The strength of this study is the comparison of con-
traceptive use among isotretinoin users compared with
contraceptive use among non-isotretinoin users. In
addition, several aspects related to prescribing isotreti-
noin and contraceptives are studied, for instance, com-
pliance related to ﬁrst prescribers and preceding
conventional anti-acne medication.
The PPP for isotretinoin contains among others a
requirement of the use of contraceptive measurements
for women of childbearing age. Preferably two meth-
ods should be used, one of which should be a barrier
method. Because of this condition for prescribing iso-
tretinoin to women of childbearing age, the use of
prescribed contraceptives in accordance with the PPP
would be ideally expected to have an almost 100%
coverage in addition to the barrier methods. In the
end, it seems that the PPP has received some attention
because of the 10%–20% higher usage of prescribed
contraceptives in the female isotretinoin users group
compared with the female general population.
The proportion of women using prescribed contra-
ceptive methods in the Dutch population by Statistics
Netherlands18 was 45% in 1998 and 46% in 2003.
According to these data, the use of prescribed contra-
ceptives reference group is comparable with the use
in the general Dutch population, justifying female
non-users of isotretinoin in the IADB.nl database as
reference.
A recent study by Teichert et al.24 showed at the
stringent analysis of contraceptive use in female isotre-
tinoin user population a comparable proportion of
contraception use with that in our analysis. The study
by Teichert et al. and our study are complementary
and provide a good insight in the compliance of con-
traception use among female isotretinoin users in the
Netherlands.
Despite the fact that CPA/EE should not be used
solely as a contraceptive, women with acne will use
this combination preparation of CPA and EE as con-
ventional anti-acne medication and contraceptive
and will continue using it as contraceptive during use
of isotretinoin despite the recommendation to stop
after treatment of 3 to 4months. If CPA/EE would
be excluded as a contraceptive, the contraception
h. j. m. j. crijns et al.1064
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compliance in female isotretinoin users would be very
low. Regulatory authorities could use this as an
opportunity to inform prescribers and pharmacists on
this phenomenon and the substantial off-label use of
CPA/EE as contraceptive.
Prescribers not following the guidelines for treat-
ment including the one on acne might also tend to
neglect the PPP of isotretinoin. This might be an
explanation for the smaller proportion of contraceptive
use among isotretinoin users without preceding con-
ventional anti-acne medication. Although it would be
expected from the overall better compliance of GPs
regarding contraceptive use in female isotretinoin
users, the compliance of GPs in the subgroup of
female isotretinoin users without preceding conven-
tional anti-acne treatment was much lower compared
with specialists.
Prescribed oral contraceptives have a pearl index of
1%–2% and therefore do not guarantee 100% preg-
nancy prevention. The pearl index is used for contra-
ceptive methods and is a rate determined by the
number of unintentional pregnancies related to 100
women years. Moreover, during the ﬁrst week after
the pill-free period, missing pills seem to occur,16
which can result in an unplanned pregnancy. In addi-
tion, it was shown that even women with fairly good
contraceptive compliance sometimes experienced
unplanned pregnancies.25 These data are a reason to
use a second contraceptive method, preferably a bar-
rier method.
The data suggest that education of prescribers and
pharmacists involved in the PPP might need speciﬁc
attention and focus to enhance the performance and
adherence, and also reminders that the PPP is manda-
tory might be helpful. Pharmacists, among others,
with the task of controlling prescriptions might feel
speciﬁcally responsible for the requirement of the
restricted prescription of isotretinoin for female users
of 30 days and the fact that there is a time limit on
the prescription of 7 days. Together with prescribers,
they might take a role in creating awareness of these
requirements.
In the database, there are more females receiving
prescribed medication than males are. In contrast,
isotretinoin has been more prescribed for male
patients (0.57%) than for female patients. This could
be due to higher prevalence of severe acne in men
compared with women or because of the terato-
genicity that isotretinoin will be less prescribed for
women (0.27%).
Compliance with use of contraceptive methods as
part of risk minimisation measures such as a PPP for
teratogenic drugs is lower than anticipated. Adherence
to the PPP is a joint responsibility of regulatory
authorities (to develop a good programme and create
awareness), prescribers (to inform patients and per-
form speciﬁc investigations), pharmacists (to monitor
adherence), and ultimately patients to adhere to spe-
ciﬁc requirements. Reasons for this low compliance
should be clariﬁed ﬁrst to implement improvements
or before further measures can be taken.
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KEY POINTS
• Compliance with the contraceptive measures in
the PPP is much lower than that aimed at 100%.
• Prescribers, patients, and pharmacists have a
joint responsibility for the performance of the
PPP.
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Box 1. Elements of the isotretinoin Pregnancy Prevention Programme.
• Contraindication pregnancy
• Information for patient (both males and females) regarding teratogenicity
• Educational material for patient (only female)
• Contraception brochure
• Informed consent form for women of childbearing potential to sign
• Pregnancy tests before, during, and after treatment of isotretinoin
• Supply restrictions of isotretinoin for women of childbearing potential to 30 days per prescription, and a prescription has a validity of 7 days
• At least one method of contraception; preferably two methods, one of which is a barrier method
• Isotretinoin should only be used by the person for which it is prescribed
• Patients using isotretinoin should not donate blood up to and including to at least 1 month after discontinuation
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